Social network
Media - Staying connected to our latest news and events
Media - Staying connected to our latest news and events


Staying connected to our latest news and events

Tools content (print, share, increase/decrease text size):


Middle area:

Press releases 2008

Press releases are intended to journalists, analysts and investors.

DIONYSOS study results showed the respective profiles of dronedarone and amiodarone

December 23, 2008

Sanofi-aventis and Novozymes announce a development and commercialization collaboration for an innovative antibiotic

December 22, 2008

INTANZA® / IDflu®, first intradermal influenza vaccine recommended in the European Union

December 18, 2008

Board of Directors dated December 17, 2008 - Corporate Governance

December 18, 2008

Sanofi-aventis was granted the 2008 China Charity Award by the Ministry of Civil Affairs of the People’s Republic of China

December 15, 2008

Sanofi-aventis and Bristol-Myers Squibb prevail before the U.S. Court of Appeals for the Federal Circuit in the U.S Plavix® patent infringement case

December 12, 2008

Changes in organisation

December 10, 2008

Results of a phase III trial on Elitek® presented at ASH Annual Meeting

December 07, 2008

Chris Viehbacher takes up his position as Chief Executive Officer

December 01, 2008

FDA intends to have an Advisory Committee meeting for Multaq® (dronedarone) on March 18, 2009

November 27, 2008

Sanofi-aventis Europe’s recommended Offer for Zentiva to remain open until February 20, 2009

November 26, 2008

Sanofi-aventis announces the settlement of Nasacort® AQ U.S. patent litigation and certain Allegra®/Allegra® D-12 U.S. patent litigations

November 19, 2008

Russia chooses inactivated Polio vaccine from Sanofi Pasteur for primary immunization of all infants

November 12, 2008

Dronedarone (Multaq®) reduced the incidence and duration of hospitalization in patients with atrial fibrillation

November 11, 2008

Sanofi Pasteur first international vaccine company to enter Japan with pediatric vaccine

November 10, 2008

Publication in the American Heart Journal of CURRENT-OASIS 7 trial design

November 06, 2008

Sanofi-aventis to discontinue all clinical trials with rimonabant

November 05, 2008

Third-quarter 2008 results

October 31, 2008

New ADA/EASD treatment recommendations: timely use of basal insulin reinforced as a “Core Therapy” for type 2 diabetes

October 30, 2008

FDA approves rapid-acting insulin Apidra® for treatment of children with diabetes

October 29, 2008

High-dose influenza vaccine shows increased immune response among adults 65 years of age and older

October 26, 2008

Sanofi-aventis is complying with the EMEA’s recommendation to temporarily suspend the marketing authorisation of Acomplia® in obese and overweight patients

October 23, 2008

Sanofi-aventis and Medicines for Malaria Venture enter into collaboration to fight Malaria

October 22, 2008

Sanofi-aventis expands its R&D presence in China

October 21, 2008

Coarsucam™ (artesunate/amodiaquine) first fixed-dose antimalarial combination to receive WHO Prequalification

October 16, 2008

Sanofi-aventis enters into collaboration with TB Alliance to fight Tuberculosis

October 14, 2008

Sanofi-aventis signs a collaboration agreement with RainDance Technologies and Louis Pasteur University to launch dScreen Consortium within “Alsace BioValley” cluster

September 26, 2008

Sanofi Pasteur completes the acquisition of Acambis

September 25, 2008

FDA approves Nasacort AQ® nasal spray for children aged 2-5 years old

September 23, 2008

Sanofi-aventis strengthens its position in the Dow Jones Sustainability World Index

September 22, 2008

Sanofi-aventis announces intention to raise offer for Zentiva to CZK 1150 in cash per share

September 22, 2008

Sanofi-aventis europe’s offer for Zentiva NV to remain open until November 28, 2008

September 18, 2008

Multi-pronged therapeutic cancer vaccine regimen to be studied in melanoma patients

September 17, 2008

New study results support the “Basal Plus” strategy with LANTUS® and APIDRA® to improve blood sugar control in patients with type 2 diabetes

September 10, 2008

People with type 2 diabetes treated with LANTUS® and APIDRA® achieved greater reductions in A1C than those treated with pre-mixed insulin

September 10, 2008

Upcoming change of Chief Executive Officer

September 10, 2008

New real life studies illustrate greater A1C lowering and cost benefit observed with LANTUS® over detemir and NPH insulin

September 08, 2008

Inauguration of the sanofi-aventis Central Anti-Counterfeit Laboratory in Tours

September 04, 2008

Further analysis from ATHENA study showed that Multaq® (dronedarone) reduced the risk of stroke in patients with atrial fibrillation

September 03, 2008

Acambis’ shareholders approve Sanofi Pasteur Holding’s offer by a large majority

September 02, 2008

Sanofi-aventis acquisition of Symbion Consumer in Australia now completed

September 01, 2008

“Taxotere® Injection” (docetaxel hydrate) approved in Japan for the treatment of prostate cancer

September 01, 2008

Multaq® (dronedarone) granted FDA Priority Review for patients with atrial fibrillation

August 08, 2008

Sanofi Pasteur shipping first doses of influenza vaccine for the 2008-2009 season in the US

August 01, 2008

Availability on line of the Group’s half-year financial report for 2008

July 31, 2008

Second quarter 2008 results

July 31, 2008

Clopidogrel in Germany

July 29, 2008

Recommended Offer by Sanofi Pasteur for Acambis plc

July 25, 2008

European Commission approved APIDRA® for treatment of children & adolescents with diabetes

July 24, 2008

Newly published study results showed that two mealtime insulin dosing algorithms were effective for patients with type 2 diabetes

July 22, 2008

Sanofi-aventis and DNDi welcome the Clinton Foundation announcement on ACTs and commit to providing fixed dose combination ASAQ at equally low prices

July 21, 2008

Sanofi-aventis enters into agreement with Primary Health Care to acquire “Symbion Consumer”, its nutraceuticals & OTC division, in Australia

July 21, 2008

Sanofi-aventis announces the termination of development and commercialization agreement for S-1 with Taiho Pharmaceutical

July 18, 2008

Sanofi-aventis signs a collaboration agreement with The Johns Hopkins University School of Medicine to find new therapies for respiratory & immuno-allergic diseases

July 17, 2008

Publication of Sanofi-aventis Europe’s Offer of CZK 1,050 in cash per share for Zentiva N.V

July 11, 2008

Sanofi Pasteur inaugurates High Tech vaccine production facility to respond to soaring demand worldwide

June 25, 2008

U.S. FDA licenses Sanofi Pasteur’s new pediatric combination vaccine, Pentacel®

June 23, 2008

Sanofi-aventis intends to make a Competing Bid of CZK 1,050 in cash per share for Zentiva

June 18, 2008

Sanofi-aventis becomes a major partner in the biotechnology field in year leading to BIO 2008

June 17, 2008

Sanofi Pasteur to donate 60 million doses of H5N1 vaccine to WHO over 3 years for its influenza vaccine global stockpile

June 16, 2008

Ambien CR® improved insomnia and daily functioning in patients with co-morbid major depressive disorder

June 10, 2008

Acomplia (rimonabant) significantly improved glucose control in type 2 diabetes patients treated with insulin

June 10, 2008

Five-year safety study examines the effect of LANTUS® on the progression of retinopathy in people with type 2 diabetes

June 10, 2008

Study shows LANTUS® helped people living with type 2 diabetes reach the ADA’s recommended target for blood sugar control

June 07, 2008

Insulin Glulisine APIDRA® efficacy in the treatment of children and adolescents with type 1 diabetes

June 07, 2008

New diabetes compound AVE0010 showed clear dose response results with once-a-day injection in phase IIb study

June 07, 2008

Sanofi-aventis and Oxford BioMedica report encouraging Trovax® Phase II trial results in metastatic renal cancer

June 02, 2008

Statement on third-party clopidogrel applications in Germany

May 28, 2008

New Eloxatin® (oxaliplatin injection) prescribing information in the U.S includes six-year overall survival data

May 28, 2008

Node-negative early stage breast cancer patients benefit from Taxotere®-based chemotherapy

May 27, 2008

ATHENA Clinical Results with Dronedarone (Multaq®) Highlighted at the World Congress of Cardiology

May 21, 2008

Sanofi-aventis and Regeneron Update Aflibercept (VEGF Trap) Clinical Development Program in Oncology

May 21, 2008

Landmark ATHENA Study Findings With Multaq® (dronedarone) Show 24% Reduction in Cardiovascular Hospitalisation or Death in Patients With Atrial Fibrillation

May 15, 2008

District Court Decision affirmed in U.S. Lovenox® (enoxaparin sodium) patent infringement case

May 15, 2008

Sanofi-aventis Annual General Meeting

May 15, 2008

Plavix®(clopidogrel) in Germany

May 09, 2008

Encouraging first-quarter 2008 results - Further positive Phase III results for eplivanserin

April 30, 2008

U.S. Government accepts $192 million of Sanofi Pasteur H5N1 bulk vaccine antigen for pandemic stockpile

April 28, 2008

Malaria: strong partnerships aiming to benefit patients in Africa

April 22, 2008

Sanofi Pasteur invests 100 million Canadian dollars in an R&D facility in Canada to Boost Innovation in Vaccine Research for Global Health

April 15, 2008

Information available concerning the Ordinary General Meeting of May 14, 2008

April 10, 2008

NICE Recommends Acomplia® to be included in the NHS Guidance

March 26, 2008

Perioperative Eloxatin®-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases

March 21, 2008

U.S. FDA Licenses DAPTACEL® Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization Series

March 13, 2008

Filing of the 2007 U.S. Form 20-F and French “Document de Référence” and Annual Financial Report

March 07, 2008

Sanofi-aventis Board of Directors

March 07, 2008

New 300mg loading dose tablet for Plavix® receives positive opinion from the European Committee for Medicinal Products (CHMP)

March 05, 2008

OneWorld Health, Amyris Biotechnologies and Sanofi-aventis Announce Development Agreement for Semisynthetic Artemisinin

March 03, 2008

Sanofi Pasteur Mounts Emergency Response to Yellow Fever Epidemic in Latin America

February 26, 2008

FDA approves XYZAL® (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria

February 19, 2008

Sanofi-aventis’ SoloSTAR® insulin pen for Lantus and Apidra receives the prestigious GOOD DESIGN Award

February 14, 2008

Sanofi Pasteur and Statens Serum Institut team up against Tuberculosis

February 14, 2008

Sanofi Pasteur files for European Approval of the first seasonal influenza vaccine delivered by intradermal microinjection

February 13, 2008

2007 earnings ahead of guidance - Sharp rise in proposed dividend

February 12, 2008

Sanofi-aventis enters into Antibody Agreements with Dyax for the fully human monoclonal antibody DX-2240 and "Phage Display Technology"

February 12, 2008

“Pathways of Solidarity” - a book and an exhibition

February 07, 2008

"My child matters": 25 programmes in 16 countries to fight childhood cancers

February 04, 2008

Clexane®/Lovenox® approved in Japan

January 28, 2008

Ambien CR® (zolpidem tartrate extended-release) tablets CIV improved chronic insomnia in patients with co-morbid generalized anxiety disorder

January 04, 2008

Sanofi Pasteur Enters Agreement with Crucell for Next-generation Biologicals against Rabies

January 03, 2008

Right area:




Filter by date


© Sanofi 2004-2016 - All rights reserved - Update: March 12, 2015

  • Site complies with W3C WCAG 2.0 (new window, in english)